EUVIMEDEUVIMED entdecken
Crossref

Therapeutic apheresis treatment in rheumatic diseases: Insights from a single‐center experience

Ezgi Çimen Güneş iD, Emre Tekgöz, Seda Çolak, Selim Sayın iD, Hülya Şirin, Meltem Aylı, Muhammet Çınar, Sedat Yılmaz

Therapeutic Apheresis and Dialysis · 2025

DOI: 10.1111/1744-9987.14199 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Apheresis and Dialysis, 2025. Verfasst von Ezgi Çimen Güneş und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Division of Rheumatology, Gulhane Training and Research Hospital, University of Health Sciences, Ankara, Turkey. Hauptthemen laut MEDLINE: Rheumatic Diseases, Blood Component Removal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

We aimed to evaluate the characteristics of the patients with a rheumatologic disease who underwent TPE.

Method

A single‐center, retrospective study was conducted between January 2016 and June 2023.

Results

Twenty patients with a median age of 51 years received a median of 6 TPE sessions. Concurrently, immunosuppressive therapy was administered to 18 (90%) of them. During the follow‐up period, 9 patients (45%) died. Creatinine ( p = 0.001), C‐reactive protein ( p = 0.001), sedimentation rate ( p = 0.002), leukocyte ( p = 0.003), thrombocyte ( p = 0.003), and neutrophil ( p = 0.003) counts was decreased after TPE. Similarly, in the ROC analysis of post TPE laboratory parameters, urea, creatinine, CRP, hemoglobin, platelets, and lymphocytes predicted mortality with areas under the curve values ranging from 0.747 to 0.869. In the Cox regression analysis for mortality, creatinine was predictive for mortality ( p = 0.030), HR 1.59 (95% CI: 1.05–2.41).

Conclusion

In rheumatologic conditions, TPE is beneficial to fill the gap until the effects of immunosuppressants become apparent.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rheumatic DiseasesBlood Component RemovalHumansMiddle AgedFemaleMaleRetrospective StudiesAdultAgedImmunosuppressive AgentsTreatment Outcome

Stichwörter der Autor:innen

catastrophic antiphospholipid antibody syndromesystemic lupus erythematosustherapeutic plasma exchangevasculitis

Substanzen

Immunosuppressive Agents

Autor:innen und Institutionen

  • Department of Internal Medicine, Division of Rheumatology, Gulhane Training and Research Hospital, University of Health Sciences, Ankara, Turkey.
  • Department of Internal Medicine, Division of Haematology, Gulhane Training and Research Hospital, University of Health Sciences, Ankara, Turkey.
  • Department of Public Health, Gulhane School of Medicine, University of Health Science, Ankara, Turkey.

ORCID-Profile: Ezgi Çimen Güneş, Selim Sayın

Zitieren

APA

Çimen Güneş, E., Tekgöz, E., Çolak, S., Sayın, S., Şirin, H., Aylı, M., Çınar, M., & Yılmaz, S. (2025). Therapeutic apheresis treatment in rheumatic diseases: Insights from a single‐center experience. Therapeutic Apheresis and Dialysis. https://doi.org/10.1111/1744-9987.14199

Vancouver

Çimen Güneş E, Tekgöz E, Çolak S, Sayın S, Şirin H, Aylı M, et al. Therapeutic apheresis treatment in rheumatic diseases: Insights from a single‐center experience. Therapeutic Apheresis and Dialysis. 2025. doi:10.1111/1744-9987.14199

BibTeX
@article{imenGne2025,
  author = {Çimen Güneş, Ezgi and Tekgöz, Emre and Çolak, Seda and Sayın, Selim and Şirin, Hülya and Aylı, Meltem and Çınar, Muhammet and Yılmaz, Sedat},
  title = {Therapeutic apheresis treatment in rheumatic diseases: Insights from a single‐center experience},
  journal = {Therapeutic Apheresis and Dialysis},
  year = {2025},
  doi = {10.1111/1744-9987.14199}
}
Kostenlos starten →